Oncology Data Advisor - Data Hub: Hematologic Malignancies

Investigating Epcoritamab for Follicular Lymphoma and Beyond With Reid Merryman, MD

Epcoritamab, a bispecific CD20-directed CD3 T-cell engager, is currently being investigated in numerous settings for patients with non-Hodgkin lymphomas. Recently, results were presented at the European Hematology Association (EHA) Congress for Cohorts 2A and 2B of the phase 1/2 EPCORE NHL-2 trial, which is investigating an epcoritamab combination for patients with relapsed/refractory follicular lymphoma. In this interview, Dr. Reid Merryman, an Attending Physician at Dana-Farber Cancer Center and one of the study's investigators, discusses the significance of these results and the efficacy of epcoritamab across the various tumor types being studied.

Investigating Epcoritamab for Follicular Lymphoma and Beyond With Reid Merryman, MD

Exploring the Approval of Epcoritamab for Diffuse Large B-Cell Lymphoma With Reid Merryman, MD

In May 2023, the FDA granted approval to epcoritamab, a CD3-redirecting, CD20-targeting bispecific antibody, for patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma. Following the approval, Oncology ...

Driving Health Care Accessibility Through Acute Myeloid Leukemia Research: National Minority Health Month With Ian Bouligny, MD

In this interview for National Minority Health Month, Oncology Data Advisor speaks with Dr. Ian Bouligny, a third-year Hematology/Oncology Fellow at Virginia Commonwealth University (VCU) Massey Cancer Center. Dr. Bouligny shares updates on his resea...

Investigating Epcoritamab for Follicular Lymphoma and Beyond With Reid Merryman, MD

Oncology Data Advisor® · Investigating Epcoritamab for Follicular Lymphoma and Beyond With Reid Merryman, MD Epcoritamab, a bispecific CD20-directed CD3 T-cell engager, is currently being investigated in numerous settings for patients with...

Coping With the Uncertainty of Indolent Non-Hodgkin Lymphoma With Richard Newcomb, MD

Oncology Data Advisor® · Coping With the Uncertainty of Indolent Non-Hodgkin Lymphoma With Richard Newcomb, MD At the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, Dr. Richard Newcomb, Hematology/Oncology Fellow at Dana...

Exploring the Primary Overall Survival Results of Axicabtagene Ciloleucel in the ZUMA-7 Trial With Jason Westin, MD

Oncology Data Advisor® · Exploring Primary Overall Survival Results of Axicabtagene Ciloleucel in ZUMA-7: Jason Westin, MD At the recent 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, Dr. Jason Westin, Director of Lympho...

Confronting Knowledge Gaps in Rare Hematologic Malignancies

In the beginning of 2022, i3 Health and Oncology Data Advisor hosted ODACon: A Rare Hematologic Malignancies Symposium, a live, virtual symposium which provided five educational activities that challenged knowledge gaps experienced by clinicians rega...

Elranatamab-bcmm Granted Accelerated Approval for Multiple Myeloma

The FDA granted accelerated approval to elranatamab-bcmm (Elrexfio™, Pfizer, Inc.) for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including one proteasome inhib...

$Talquetamab-tgvs Granted Accelerated Approval for Relapsed/Refractory Multiple Myeloma$

Talquetamab-tgvs Granted Accelerated Approval for Relapsed/Refractory Multiple Myeloma

The FDA has granted accelerated approval to talquetamab-tgvs (Talvey™, Janssen Biotech, Inc.) for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least 4 prior lines of therapy, including a proteasome...